A Phase 2 interventional study of Clindamycin Phosphate and Triamcinolone Acetonide in Glioblastoma, Recurrent Glioblastoma and Skin Toxicity, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Glioblastoma by Memorial Sloan Kettering Cancer Center — 3 open to participants now, 6 under way, none of them phase 3. Glioblastoma · Memorial Sloan Kettering Cancer Center.
Among the 21 studies in Glioblastoma by Memorial Sloan Kettering Cancer Center, this one is the 6th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2020, is one of 9 in phase 2, and was the 17th registered.
2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →3 of the 21 studies in Glioblastoma by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 10
First in 1997; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is above the median of 36 across 1,758 interventional studies indexed under Glioblastoma.
Median enrollment 44 across the 14 interventional studies, 309 across the 1 observational. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.
5 of the studies in Glioblastoma by Memorial Sloan Kettering Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03743662Memorial Sloan Kettering Cancer CenterNivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma | 2026-11 |
| NCT02375841Memorial Sloan Kettering Cancer CenterCoping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers | 2027-02 |
| NCT04469075Memorial Sloan Kettering Cancer CenterClindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields | 2027-07 |
| NCT06058988Memorial Sloan Kettering Cancer CenterTrastuzumab Deruxtecan (T-DXd) for People With Brain Cancer | 2027-09-22 |
| NCT07223034Memorial Sloan Kettering Cancer CenterA Study of 177Lu-PSMA-617 in People With Gliomas | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 21 studies in Glioblastoma by Memorial Sloan Kettering Cancer Center, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The participants are being treated with Tumor Treating Fields (TTFields) for malignant glioma, and this type of treatment may cause skin-related side effects. This study will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects of TTFields.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who are scheduled to receive TTFields therapy for newly diagnosed GBM will be treated with: topical clindamycin (or approved equivalent) 1% and triamcinolone 0.1%. Participating sites may use an alternative equivalent form of clindamycin, such as a gel, with MSK PI approval
Drug: Clindamycin Phosphate · Drug: Triamcinolone Acetonide
phosphate 1% solution triamcinolone 0.01% at every array change (or approved equivalent)
triamcinolone acetonide 0.01% lotion triamcinolone 0.01% at every array change
Number of patients without grade 2 or higher skin toxicity
device-related skin adverse events by investigator assessment.
Time frame: up to 120 days
skin-related quality of life
using the PRO-CTCAE for rash, ulcer, and pruritus.
Time frame: up to 120 days
Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Started Jul 2020 (actual). Primary completion is estimated for Jul 2027, 84 months after the start.
Of 197 non-industry phase 2 interventional studies under Glioblastoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 84 months is above that.
Counting every sponsor, half of 248 studies reached it within 55 months; a quarter within 40 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clindamycin phosphate
Memorial Sloan Kettering Cancer Center →